Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.lungcan.2021.05.019
Title: Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis
Authors: Zhu, Viola W.
Zhao, Joseph J.
Gao, Yanfei
Syn, Nicholas L.
Zhang, Shannon S.
Ou, Sai-Hong Ignatius
Bauer, Kenneth A.
Nagasaka, Misako
Keywords: ALK+ NSCLC
Cumulative incidence
Deep vein thrombosis
Meta-analysis
Pulmonary embolism
ROS1+ NSCLC
Systematic review
Thromboembolism
Issue Date: 1-Jul-2021
Publisher: Elsevier Ireland Ltd
Citation: Zhu, Viola W., Zhao, Joseph J., Gao, Yanfei, Syn, Nicholas L., Zhang, Shannon S., Ou, Sai-Hong Ignatius, Bauer, Kenneth A., Nagasaka, Misako (2021-07-01). Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer 157 : 147-155. ScholarBank@NUS Repository. https://doi.org/10.1016/j.lungcan.2021.05.019
Rights: Attribution 4.0 International
Abstract: Introduction: Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). Materials and Methods: Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis respectively for either ALK+ or ROS1+ NSCLC patients. Results: We identified eight studies (766 ALK+, 143 ROS1+, 2314 non-ALK+ and non-ROS1+ NSCLC patients) for the meta-analysis. For ALK+ NSCLC, the pooled OR was 2.00 (95% CI: 1.60-2.50) for total TE (TTE) by random-effects model, 2.10 (95% CI: 1.70-2.60) for venous thromboembolism (VTE), and 1.24 (95% CI: 0.80-1.91) for arterial thromboembolism (ATE). For ROS1+ NSCLC, the pooled OR was 3.08 (95% CI: 1.95-4.86) for TTE, and 3.15 (95% CI: 1.83-5.43) for VTE. Six studies (739 ALK+, 137 ROS1+, 561 EGFR+, 714 “wildtype” NSCLC patients) were included in the time-to-event analysis. The TTE incidence rate was 17.4 (95% CI: 15.3-19.5) per 100 pateint-years for ALK+ NSCLC, and 32.1 (95% CI: 24.6-39.6) per 100 patient-years for ROS1+ NSCLC with a 50 % cumulative incidence rate at year 3 of diagnosis. HR for TTE was 2.35 (95% CI: 1.90-2.92, p < 0.001) and 3.23 (95% CI: 2.40-4.34, p < 0.001) for ALK+ and ROS1+ NSCLC, respectively. Comparing ROS1+ NSCLC to ALK+ NSCLC, HR for TTE was 1.37 (95% CI: 1.05-1.79, p = 0.020). Conclusions: ALK+ and ROS1+ NSCLC patients had an increased risk of TE. ROS1+ NSCLC had further increased risk of TE over ALK+ NSCLC. © 2021 The Author(s)
Source Title: Lung Cancer
URI: https://scholarbank.nus.edu.sg/handle/10635/233505
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2021.05.019
Rights: Attribution 4.0 International
Appears in Collections:Students Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_lungcan_2021_05_019.pdf4.67 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

10
checked on Oct 26, 2022

Page view(s)

2
checked on Nov 17, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons